Global & Regional Health Technology Assessment最新文献_第5页

Prontuari Terapeutici Regionali in Italia: stato dell’arte e prospettive future. 意大利的地区治疗方案：技术水平和未来前景。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2024-03-08 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2677

Alberto Bortolami, Claudio Jommi, Filippo Bresciani, Luca Piccoli, Elisa Sangiorgi, Giovanna Scroccaro

引用次数: 0

Costo per Number Needed to Treat (NNT) di upadacitinib nel trattamento dei pazienti bio-exposed con rettocolite ulcerosa attiva da moderata a grave. 奥达帕替尼治疗生物暴露的中重度活动性溃疡性直肠结肠炎患者的单位治疗人数成本（NNT）。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2024-03-07 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2658

Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio

引用次数: 0

Regolamento HTA: come si sta muovendo l’Italia? HTA 法规：意大利在做什么？

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2024-03-05 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.3025

Francesca Patarnello

引用次数: 0

Costo per NNT di upadacitinib nel trattamento dei pazienti con dermatite atopica da moderata a severa in Italia. 意大利奥达帕替尼治疗中重度特应性皮炎患者的每 NNT 成本。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2024-02-16 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2728

Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

引用次数: 0

Il burden clinico ed economico delle complicanze della cute peristomale: un’analisi di Activity Based Costing. 肛周皮肤并发症的临床和经济负担：基于活动成本的分析。

IF 0.4

Global & Regional Health Technology Assessment Pub Date : 2024-01-23 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2639

Agostino Fortunato, Filippo Rumi, Massimo Zazzetta, Marco Della Valle, Vincenzo Pedace, Americo Cicchetti

引用次数: 0

Il futuro delle forme di distribuzione dei farmaci in regime di Servizio Sanitario Nazionale. 国家医疗卫生服务机构药品配送形式的未来。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2619

Massimo Medaglia, Giuliano Buzzetti, Marco Cossolo, Paola Deambrosis, Giovanna Scroccaro

引用次数: 0

Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP). 意大利因慢性肾病相关性瘙痒症（CKD-aP）而接受血液透析治疗的患者的医疗资源消耗情况。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2024-01-15 eCollection Date: 2024-01-01 DOI: 10.33393/grhta.2024.2696

Silvia Calabria, Lucio Manenti, Giulia Ronconi, Carlo Piccinni, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini

{"title":"Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP).","authors":"Silvia Calabria, Lucio Manenti, Giulia Ronconi, Carlo Piccinni, Letizia Dondi, Leonardo Dondi, Antonella Pedrini, Immacolata Esposito, Alice Addesi, Filippo Aucella, Nello Martini","doi":"10.33393/grhta.2024.2696","DOIUrl":"10.33393/grhta.2024.2696","url":null,"abstract":"Background: Chronic kidney disease-associated pruritus (CKD-aP) affects patients on hemodialysis. This study identified hemodialysis patients presumably affected or not affected by CKD-aP and integrated healthcare costs, from the perspective of the Italian administrative healthcare data.Methods: Through cross-linkage of Italian administrative healthcare data collected between 2015 and 2017 (accrual period) in the database of Fondazione ReS (Ricerca e Salute), patients undergoing in-hospital/outpatient hemodialysis were selected. Cohorts with and without CKD-aP were created based on the presence/absence of CKD-aP-related treatment (according to common clinical practice and guidelines) supplies and assessed in terms of CKD-aP-related treatments and mean healthcare costs per capita paid by the Italian National Health Service (INHS).Results: Of 1,239 people on hemodialysis for ≥2 years, CKD-aP affected 218 patients. Patients with CKD-aP were older and with more comorbidities. During the follow-up year, on average, the INHS spent €37,065 per case, €31,286 per control and € 35,988 per non-CKD-aP subject. High-efficiency dialytic therapies performed to people on hemodialysis with CKD-aP largely weighed on the overall mean annual cost.Conclusions: This real-world study identified patients on chronic hemodialysis potentially treated for CKD-aP. Interestingly, high-efficiency dialysis seems the most frequent and expensive choice for the treatment of CKD-aP. The discovery of appropriate and effective treatments for this condition might offer cost offsets.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"11 ","pages":"22-30"},"PeriodicalIF":0.5,"publicationDate":"2024-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10792387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139484946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Farmaci orfani in Italia: disponibilità e tempi di accesso a livello regionale. 意大利的 "孤儿药"：地区供应和获取时间。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2023-12-28 eCollection Date: 2023-01-01 DOI: 10.33393/grhta.2023.2641

Maria Lucia Marino, Eva Alessi, Aurora Di Filippo, Barbara Polistena, Francesco Macchia, Federico Spandonaro, Francesco Trotta

引用次数: 0

Time to market access in Italia: durata del processo di P&R per i farmaci per le malattie rare. 意大利市场准入时间：罕见病药物的研发过程持续时间。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2023-10-31 eCollection Date: 2023-01-01 DOI: 10.33393/grhta.2023.2610

Andrea Marcellusi, Paola Raimondo, Carlotta Galeone, Pier Luigi Canonico

{"title":"Time to market access in Italia: durata del processo di P&R per i farmaci per le malattie rare.","authors":"Andrea Marcellusi, Paola Raimondo, Carlotta Galeone, Pier Luigi Canonico","doi":"10.33393/grhta.2023.2610","DOIUrl":"10.33393/grhta.2023.2610","url":null,"abstract":"Time to market access in Italy: duration of the P&R process for rare disease drugs Objective: This paper aims to investigate the duration of the pricing & reimbursement (P&R) procedures submitted in Italy by pharmaceutical marketing authorization holders (MAH) for drugs indicated for rare diseases. Methods: All the data used in this analysis were publicly available on different sources of the Italian Ministry of Health, the Italian Medicines Agency (AIFA) and other official websites. The information was systematically collected to investigate the timeline (days) needed to complete the P&R process. The process was divided into 6 simplified steps and the median and range of days needed for each phase were estimated based on data reported in official/published documents. The analysis was stratified considering every single step of the assessment phase and included segmentation of drugs into indications for rare diseases, Orphan designation, Innovation assessment and Managed entry agreements (MEAs). Results: Overall, 181 first indication procedures were submitted to AIFA in the period considered and, of these, 167 (92.3%) were completed and 129 procedures were considered for the final analysis and the median duration of the entire process (MAH submission to final Gazette publication) was 434 days (range 176.0-918.0). The duration of procedures for rare diseases (n = 53) was longer than those for non-rare-disease procedures (n = 76) (463.0 days vs 407.5 days respectively). Among rare disease procedures, orphan designation and MEAs represent predictors for time prolongation while innovation is associated with a shorter assessment time. Conclusion: The study describes the time spent in each phase of the assessment and the appraisal process and demonstrates that uncertainty represents the main driver for the increment in the overall time.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"10 ","pages":"79-88"},"PeriodicalIF":0.5,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71524075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Il bisogno insoddisfatto: definizioni, evidenze di letteratura e implicazioni per l’HTA. 未满足的需求：HTA的定义、文献证据和含义。

IF 0.5

Global & Regional Health Technology Assessment Pub Date : 2023-10-02 eCollection Date: 2023-01-01 DOI: 10.33393/grhta.2023.2624

Claudio Jommi, Michela Meregaglia, Carmine Pinto

{"title":"Il bisogno insoddisfatto: definizioni, evidenze di letteratura e implicazioni per l’HTA.","authors":"Claudio Jommi, Michela Meregaglia, Carmine Pinto","doi":"10.33393/grhta.2023.2624","DOIUrl":"10.33393/grhta.2023.2624","url":null,"abstract":"Unmet need: definitions, literature evidence and implications for HTA The present paper illustrates the definition of unmet need provided by the peer-reviewed literature and the Health Technology Assessment (HTA) authorities across Europe in the assessment and appraisal process and within the early access schemes for medicines. The analysis relied on a descriptive review of the peer-reviewed literature and HTA documents on the definition of need (disease severity) and the way it is satisfied (existence and validity of alternatives). HTA agencies were found using (i) a narrow definition of need, focused on the clinical impact and the impact on health-related quality of life of the disease and (ii) a broad definition of comparators, including treatments used off-label in the clinical practice. Most of the contributions of the literature advocated for a broader definition of need, including additional dimensions (for example, the socio-economic impact of the disease) and the effects of existing treatments beyond their risk-benefit profile (for example, acceptability to patients). On the one hand, these contributions should be considered by HTA agencies, considering its multi-disciplinary and multi-stakeholder nature. On the other one, the explicit inclusion of the unmet need domains, at present disregarded, should depend on the decisions taken on the ground of the assessment.","PeriodicalId":12627,"journal":{"name":"Global & Regional Health Technology Assessment","volume":"10 ","pages":"70-78"},"PeriodicalIF":0.5,"publicationDate":"2023-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/96/f6/grhta-10-70.PMC10551671.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41139058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0